Deals
Bristol-Myers Makes $1.6 Billion in Deals Boosting Cancer
This article is for subscribers only.
Bristol-Myers Squibb Co. announced two deals valued at a total of about $1.6 billion that will further strengthen the drugmaker’s oncology pipeline.
The deals with Flexus Biosciences Inc. and Rigel Pharmaceuticals Inc. will add to Bristol-Myers’s portfolio of treatments that use the body’s own immune system to fight cancer. New York-based Bristol-Myers has shed units in other areas to focus heavily on a new generation of oncology treatments,